Motley Fool Asset Management LLC Purchases 15,240 Shares of Globus Medical, Inc. (NYSE:GMED)

Motley Fool Asset Management LLC increased its position in shares of Globus Medical, Inc. (NYSE:GMED - Free Report) by 9.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 171,448 shares of the medical device company's stock after acquiring an additional 15,240 shares during the period. Globus Medical comprises 0.7% of Motley Fool Asset Management LLC's holdings, making the stock its 28th largest holding. Motley Fool Asset Management LLC owned approximately 0.13% of Globus Medical worth $14,180,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in GMED. SBI Securities Co. Ltd. bought a new stake in shares of Globus Medical during the 4th quarter valued at approximately $27,000. Quarry LP grew its stake in shares of Globus Medical by 698.4% during the third quarter. Quarry LP now owns 495 shares of the medical device company's stock worth $35,000 after buying an additional 433 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Globus Medical by 60.2% during the fourth quarter. UMB Bank n.a. now owns 548 shares of the medical device company's stock worth $45,000 after buying an additional 206 shares during the last quarter. V Square Quantitative Management LLC increased its holdings in shares of Globus Medical by 52.0% during the fourth quarter. V Square Quantitative Management LLC now owns 576 shares of the medical device company's stock worth $48,000 after buying an additional 197 shares in the last quarter. Finally, First Horizon Advisors Inc. lifted its stake in shares of Globus Medical by 24.7% in the 4th quarter. First Horizon Advisors Inc. now owns 666 shares of the medical device company's stock valued at $55,000 after acquiring an additional 132 shares during the last quarter. 95.16% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO Keith W. Pfeil sold 14,167 shares of the company's stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $88.29, for a total transaction of $1,250,804.43. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 18.54% of the stock is owned by insiders.

Globus Medical Stock Up 0.8 %

GMED traded up $0.56 during trading on Tuesday, reaching $71.31. 304,019 shares of the stock traded hands, compared to its average volume of 1,029,903. The stock's 50-day moving average is $79.74 and its 200 day moving average is $80.10. Globus Medical, Inc. has a 12 month low of $49.33 and a 12 month high of $94.93. The stock has a market capitalization of $9.81 billion, a PE ratio of 95.11, a P/E/G ratio of 1.61 and a beta of 1.28.

Globus Medical (NYSE:GMED - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical device company reported $0.84 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.10. The business had revenue of $657.29 million during the quarter, compared to the consensus estimate of $646.19 million. Globus Medical had a return on equity of 10.83% and a net margin of 4.09%. As a group, equities research analysts anticipate that Globus Medical, Inc. will post 3.44 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Barclays upped their target price on Globus Medical from $100.00 to $103.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. Stifel Nicolaus upped their price objective on Globus Medical from $92.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Roth Mkm lifted their target price on shares of Globus Medical from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Tuesday, December 17th. StockNews.com lowered shares of Globus Medical from a "buy" rating to a "hold" rating in a report on Friday, March 21st. Finally, Wells Fargo & Company dropped their price target on shares of Globus Medical from $95.00 to $93.00 and set an "overweight" rating for the company in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $97.09.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.